PL3898607T3 - Glutaran 3-(1,2,3,6-tetrahydropirydyn-2-ylo)pirydyny lub jego farmaceutycznie dopuszczalny solwat - Google Patents

Glutaran 3-(1,2,3,6-tetrahydropirydyn-2-ylo)pirydyny lub jego farmaceutycznie dopuszczalny solwat

Info

Publication number
PL3898607T3
PL3898607T3 PL19829499.3T PL19829499T PL3898607T3 PL 3898607 T3 PL3898607 T3 PL 3898607T3 PL 19829499 T PL19829499 T PL 19829499T PL 3898607 T3 PL3898607 T3 PL 3898607T3
Authority
PL
Poland
Prior art keywords
tetrahydropyridin
pharmaceutically acceptable
acceptable solvate
glutarate
pyridine
Prior art date
Application number
PL19829499.3T
Other languages
English (en)
Inventor
Anatoly Mazurov
Original Assignee
Philip Morris Products S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philip Morris Products S.A. filed Critical Philip Morris Products S.A.
Publication of PL3898607T3 publication Critical patent/PL3898607T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL19829499.3T 2018-12-17 2019-12-17 Glutaran 3-(1,2,3,6-tetrahydropirydyn-2-ylo)pirydyny lub jego farmaceutycznie dopuszczalny solwat PL3898607T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18213200 2018-12-17
PCT/EP2019/085598 WO2020127225A1 (en) 2018-12-17 2019-12-17 3-(1,2,3,6-tetrahydropyridin-2-yl)pyridine glutarate or a pharmaceutically acceptable solvate thereof

Publications (1)

Publication Number Publication Date
PL3898607T3 true PL3898607T3 (pl) 2024-03-18

Family

ID=64744512

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19829499.3T PL3898607T3 (pl) 2018-12-17 2019-12-17 Glutaran 3-(1,2,3,6-tetrahydropirydyn-2-ylo)pirydyny lub jego farmaceutycznie dopuszczalny solwat

Country Status (19)

Country Link
US (1) US20210395218A1 (pl)
EP (1) EP3898607B1 (pl)
JP (1) JP2022514283A (pl)
KR (1) KR20210104666A (pl)
CN (1) CN113039180A (pl)
AU (1) AU2019407661A1 (pl)
BR (1) BR112021009580A2 (pl)
CA (1) CA3116524A1 (pl)
CL (1) CL2021001583A1 (pl)
CO (1) CO2021009186A2 (pl)
EC (1) ECSP21052586A (pl)
ES (1) ES2964561T3 (pl)
HU (1) HUE063731T2 (pl)
IL (1) IL283923A (pl)
MX (1) MX2021006867A (pl)
PH (1) PH12021550875A1 (pl)
PL (1) PL3898607T3 (pl)
WO (1) WO2020127225A1 (pl)
ZA (1) ZA202102058B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3185270A1 (en) 2020-09-03 2022-03-10 Fabiana SPADARO Low hygroscopicity active powder compositions
MX2023002465A (es) 2020-09-03 2023-03-23 Philip Morris Products Sa Composiciones en polvo activas de baja higroscopicidad secadas por congelacion.
CN116171149A (zh) 2020-09-03 2023-05-26 菲利普莫里斯生产公司 喷雾干燥的低吸湿性活性粉末组合物
EP4274574A1 (en) * 2021-01-07 2023-11-15 Philip Morris Products S.A. Compositions comprising anatabine and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
US5942244A (en) 1997-07-31 1999-08-24 Farmo-Nat Ltd. Local oral herbal slow release tablets
US6090411A (en) 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
CN2719043Y (zh) 2004-04-14 2005-08-24 韩力 雾化电子烟
EP2549995B1 (en) 2010-03-23 2021-04-21 Philip Morris Products S.A. Use of anatabine to treat inflammation and methods of synthesizing anatabine
US8207346B2 (en) 2010-03-23 2012-06-26 Rock Creek Pharmaceuticals, Inc. Methods of synthesizing anatabine
US8241680B2 (en) 2010-06-30 2012-08-14 Rock Creek Pharmaceuticals, Inc. Nutraceutical product containing anatabine and yerba maté
CA2847199C (en) 2011-08-29 2022-03-22 Rock Creek Pharmaceuticals, Inc. Product comprising anatabine or salts thereof, vitamin a and vitamin d3 and pharmaceutical compositions thereof used for anti-inflammation support
WO2015009500A1 (en) 2013-07-19 2015-01-22 Williams Jonnie R Volatilized delivery of anatabine for treatment of substance addiction

Also Published As

Publication number Publication date
KR20210104666A (ko) 2021-08-25
ES2964561T3 (es) 2024-04-08
CA3116524A1 (en) 2020-06-25
PH12021550875A1 (en) 2021-10-18
MX2021006867A (es) 2021-07-02
AU2019407661A1 (en) 2021-04-29
CN113039180A (zh) 2021-06-25
EP3898607B1 (en) 2023-10-18
ECSP21052586A (es) 2021-08-31
JP2022514283A (ja) 2022-02-10
WO2020127225A1 (en) 2020-06-25
CO2021009186A2 (es) 2021-08-30
ZA202102058B (en) 2022-09-28
CL2021001583A1 (es) 2021-11-26
BR112021009580A2 (pt) 2021-08-17
EP3898607A1 (en) 2021-10-27
EP3898607C0 (en) 2023-10-18
HUE063731T2 (hu) 2024-01-28
IL283923A (en) 2021-07-29
US20210395218A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
IL283923A (en) 3-(6,3,2,1-tetrahydropyridin-2-yl)pyridine glutarate or its pharmaceutically acceptable solvate
DK3846904T3 (da) 5-morpholin-4-yl-pyrazolo[4,3-b]pyridinderivater
IL288802A (en) Benzisoxazole sulfonamide derivatives
IL276952A (en) History of 4,2-diaminoquinazolines and their medicinal uses
EP3857908A4 (en) MODULAR IN-EAR DEVICE
IL282428A (en) History of pyridinyl sulfonamide, pharmaceutical preparations and their uses
RS60224B1 (sr) Derivati 3-(karboksimetil)-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana
EP3833343A4 (en) HETEROCYCLIC FLAVON DERIVATIVES, COMPOSITIONS AND RELATED METHODS THEREOF
IL290882A (en) Pyrazole compounds, their formulations and methods of using the compounds and/or formulations
EP3743018A4 (en) KNEE PROSTHESIS WITH PIVOT SUPPORT
GB2590189B (en) Lycorine derivative, and pharmaceutical composition and use thereof
SG11202004594SA (en) Anti-hbv tetrahydroisoxazolo[4,3-c]pyridine compounds
EP4151632A4 (en) 1,4,5,6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE
EP4062877C0 (en) MODULAR TIBIAL EXTRACTOR JAW
IL282999A (en) 4,3,1-oxadiazolone compound and drug
GB202015822D0 (en) 66.123.142648/01
EP3862059A4 (en) MODULAR GAME
PL4021900T3 (pl) 2,2,6-trimetylo-4,5-dihydro-3h-oksepina jako składnik aromatowy
GB202013791D0 (en) Tidysqueeze 9
WO2019203748A3 (en) The composition comprising raloxifene with at least one antipsychotic agent
GB201913527D0 (en) Nodens 2
GB201910340D0 (en) CAERvest 1
GB201910320D0 (en) Aleck 1
SG11202012760SA (en) METHOD FOR PRODUCING a-AZIDOANILINE DERIVATIVE OR a,a'-DIAZIDE DERIVATIVE
GB201904443D0 (en) Aerocar 1